To check the asthmatic status of the rats and validate the model, after immunization and administration of OVA and the consequent treatments with the drug of choice (MP) and the novel alternative treatment (CPC), Figure 1 shows clinical pathology markers of asthma that rise in the OVA-induced asthma group, where there is leukocytosis, an increase in venous and arterial CO2 concentration and increased pulmonary MPO activity. This evidence concerns the gene MPO and Increased total leukocyte count.